多基因风险评分与慢性淋巴细胞白血病及单克隆B细胞增多症风险的关联
研究利用41个代表性单核苷酸多态性构建多基因风险评分,在InterLymph联盟1499例慢性淋巴细胞白血病和2459例对照中评估其与慢性淋巴细胞白血病风险的关联,并在独立样本中验证,同时分析其与单克隆B细胞增多症风险的关联及家族史的混杂影响。
要点
- 连续多基因风险评分与慢性淋巴细胞白血病风险强相关,InterLymph联盟OR为2.49。
- 在遗传流行病学联盟和Mayo对照中验证,OR为3.02,c-statistic为0.78。
- 连续多基因风险评分与单克隆B细胞增多症风险亦高度显著相关,OR为2.81。
核心结论
- 验证后的多基因风险评分与慢性淋巴细胞白血病风险强相关,并提供家族史之外的信息。
- 多基因风险评分可用于识别慢性淋巴细胞白血病高风险个体及单克隆B细胞增多症风险增高个体。
研究设计与样本
- 发现阶段:汇总InterLymph联盟1499例慢性淋巴细胞白血病和2459例对照的41个代表性单核苷酸多态性基因型数据。
- 验证阶段:使用遗传流行病学联盟201例慢性淋巴细胞白血病、95例单克隆B细胞增多症、144例有慢性淋巴细胞白血病家族史的对照及Mayo Clinic 1267例对照的数据。
- 采用比值比评估疾病与多基因风险评分的关联,用c-statistic评估判别准确性。
主要发现
- InterLymph联盟中,连续多基因风险评分与慢性淋巴细胞白血病风险强相关(OR,2.49;P = 4.4 × 10-94)。
- 在遗传流行病学联盟和Mayo对照中重复出该发现(OR,3.02;P = 7.8 × 10-30),并观察到高判别力(c-statistic = 0.78)。
- 与家族史联合建模时,多基因风险评分与家族史状态均保留显著性。
- 连续多基因风险评分与单克隆B细胞增多症风险高度显著相关(OR,2.81;P = 9.8 × 10-16)。
关键数值与推荐
- 连续多基因风险评分与慢性淋巴细胞白血病风险的OR为2.49(P = 4.4 × 10-94)。
- 连续多基因风险评分与慢性淋巴细胞白血病风险的验证OR为3.02(P = 7.8 × 10-30),c-statistic = 0.78。
- 连续多基因风险评分与单克隆B细胞增多症风险的OR为2.81(P = 9.8 × 10-16)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers. For discovery, we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the InterLymph Consortium. For validation, we used data from 1267 controls from Mayo Clinic and 201 CLL, 95 MBL, and 144 controls with a FH of CLL from the Genetic Epidemiology of CLL Consortium. We used odds ratios (ORs) to estimate disease associations with PRS and c-statistics to assess discriminatory accuracy. In InterLymph, the continuous PRS was strongly associated with CLL risk (OR, 2.49; P = 4.4 × 10-94). We replicated these findings in the Genetic Epidemiology of CLL Consortium and Mayo controls (OR, 3.02; P = 7.8 × 10-30) and observed high discrimination (c-statistic = 0.78). When jointly modeled with FH, PRS retained its significance, along with FH status. Finally, we found a highly significant association of the continuous PRS with MBL risk (OR, 2.81; P = 9.8 × 10-16). In conclusion, our validated PRS was strongly associated with CLL risk, adding information beyond FH. The PRS provides a means of identifying those individuals at greater risk for CLL as well as those at increased risk of MBL, a condition that has potential clinical impact beyond CLL.
引用
- Kleinstern G, Camp NJ, Goldin LR, et al. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood. 2018. PMID: 29674426. doi:10.1182/blood-2017-11-814608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。